{"nctId":"NCT01332968","briefTitle":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","startDateStruct":{"date":"2011-07-06","type":"ACTUAL"},"conditions":["Non-Hodgkin's Lymphoma"],"count":1401,"armGroups":[{"label":"Rituximab+Chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Doxorubicin","Drug: Vincristine","Drug: Prednisone","Drug: Bendamustine","Drug: Rituximab"]},{"label":"Obinutuzumab+Chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Obinutuzumab","Drug: Cyclophosphamide","Drug: Doxorubicin","Drug: Vincristine","Drug: Prednisone","Drug: Bendamustine"]}],"interventions":[{"name":"Obinutuzumab","otherNames":["GA101; RO5072759"]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"Doxorubicin","otherNames":[]},{"name":"Vincristine","otherNames":[]},{"name":"Prednisone","otherNames":[]},{"name":"Bendamustine","otherNames":[]},{"name":"Rituximab","otherNames":["MabThera/Rituxan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cluster of differentiation 20 (CD20)-positive indolent B-cell non-Hodgkin's lymphoma (follicular lymphoma or splenic, nodal or extranodal marginal zone lymphoma)\n* Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to \\[\\>/=\\] 7 centimeters \\[cm\\])\n* For participants with follicular lymphoma: requirement for treatment according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria\n* For participants with symptomatic splenic, nodal, or non-gastric extranodal marginal zone lymphoma: disease that is de novo or has relapsed following local therapy (i.e. surgery or radiotherapy) and requires therapy as assessed by the investigator\n* At least one bi-dimensionally measurable lesion (greater than \\[\\>\\] 2 cm in its largest dimension by computed tomography \\[CT\\] scan or magnetic resonance imaging \\[MRI\\])\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n* Adequate hematologic function\n\nExclusion Criteria:\n\n* Central nervous system lymphoma, leptomeningeal lymphoma, or histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma\n* Grade 3b follicular lymphoma, small lymphocytic lymphoma or Waldenstr√∂m's macroglobulinaemia\n* Ann Arbor Stage I disease\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy\n* Known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol\n* For participants with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy\n* For participants with non-follicular lymphoma: prior treatment with chemotherapy or immunotherapy\n* Regular treatment with corticosteroids during the 4 weeks prior to the start of Cycle 1\n* Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results\n* For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (\\<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram\n* History of prior other malignancy with the exception of curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study\n* Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1\n* Vaccination with a live vaccine within 28 days prior to randomization\n* Recent major surgery (within 4 weeks prior to start of Cycle 1), other than for diagnosis\n* Abnormal laboratory values as defined by protocol for creatinine, creatinine clearance, aspartate transaminase (AST) or alanine transaminase (ALT), total bilirubin, international normalized ration (INR), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPPT), unless these abnormalities are due to underlying lymphoma\n* Positive test results for human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV1), hepatitis C or chronic hepatitis B\n* Pregnant or lactating women\n* Life expectancy \\<12 months\n* Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed","description":"Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"16.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed","description":"Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"34.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival in the Overall Study Population, Investigator-Assessed","description":"Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by CT/MRI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5","spread":null},{"groupId":"OG001","value":"34.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed","description":"Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)","description":"Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by CT/MRI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"18.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (Follicular Lymphoma Population), Investigator-Assessed","description":"Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as \\>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%. Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null},{"groupId":"OG001","value":"88.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (Overall Study Population), Investigator-Assessed","description":"Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as \\>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"87.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response (Follicular Lymphoma Population), Investigator-Assessed","description":"Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"62.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response (Overall Study Population), Investigator-Assessed","description":"Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (Follicular Lymphoma Population), IRC-Assessed","description":"Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \\>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%. Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":null},{"groupId":"OG001","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (Overall Study Population), IRC-Assessed","description":"Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as \\>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"89.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response (Follicular Lymphoma Population), IRC-Assessed","description":"Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"28.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":null},{"groupId":"OG001","value":"71.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response (Overall Study Population), IRC-Assessed","description":"Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"69.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Follicular Lymphoma Population)","description":"Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Overall Study Population)","description":"Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival (Follicular Lymphoma Population)","description":"Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"35.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival (Overall Study Population)","description":"Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival (Follicular Lymphoma Population)","description":"Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival (Overall Study Population)","description":"Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed","description":"DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \\>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) (Overall Study Population), Investigator-Assessed","description":"DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as \\>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)","description":"Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"26.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Next Anti-Lymphoma Treatment (Overall Study Population)","description":"Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"15.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)","description":"FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.36","spread":"4.77"},{"groupId":"OG001","value":"23.14","spread":"4.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"4.54"},{"groupId":"OG001","value":"-0.21","spread":"4.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"4.83"},{"groupId":"OG001","value":"0.56","spread":"5.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"4.76"},{"groupId":"OG001","value":"1.42","spread":"5.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"4.29"},{"groupId":"OG001","value":"1.34","spread":"4.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"4.54"},{"groupId":"OG001","value":"1.33","spread":"5.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.84","spread":"4.92"},{"groupId":"OG001","value":"23.28","spread":"4.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"4.03"},{"groupId":"OG001","value":"-0.67","spread":"3.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"4.77"},{"groupId":"OG001","value":"-0.56","spread":"5.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"4.72"},{"groupId":"OG001","value":"-0.67","spread":"4.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"5.56"},{"groupId":"OG001","value":"-0.97","spread":"5.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"5.67"},{"groupId":"OG001","value":"-0.71","spread":"5.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.64","spread":"4.19"},{"groupId":"OG001","value":"17.87","spread":"4.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"3.40"},{"groupId":"OG001","value":"1.35","spread":"3.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"3.90"},{"groupId":"OG001","value":"1.14","spread":"3.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"3.88"},{"groupId":"OG001","value":"1.49","spread":"4.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"3.92"},{"groupId":"OG001","value":"1.46","spread":"3.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"3.98"},{"groupId":"OG001","value":"1.49","spread":"3.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.66","spread":"6.19"},{"groupId":"OG001","value":"18.76","spread":"5.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"5.30"},{"groupId":"OG001","value":"-0.07","spread":"5.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"5.63"},{"groupId":"OG001","value":"0.93","spread":"5.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"5.31"},{"groupId":"OG001","value":"1.25","spread":"6.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":"5.54"},{"groupId":"OG001","value":"1.65","spread":"5.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"6.12"},{"groupId":"OG001","value":"1.72","spread":"6.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)","description":"The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.61","spread":"18.16"},{"groupId":"OG001","value":"86.94","spread":"18.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"15.03"},{"groupId":"OG001","value":"2.18","spread":"15.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"17.00"},{"groupId":"OG001","value":"4.57","spread":"16.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.22","spread":"16.16"},{"groupId":"OG001","value":"7.17","spread":"16.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.61","spread":"15.62"},{"groupId":"OG001","value":"7.20","spread":"16.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.23","spread":"17.06"},{"groupId":"OG001","value":"7.44","spread":"16.96"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)","description":"The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.01","spread":"9.37"},{"groupId":"OG001","value":"45.54","spread":"9.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"7.18"},{"groupId":"OG001","value":"2.71","spread":"7.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.99","spread":"8.63"},{"groupId":"OG001","value":"3.01","spread":"8.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":"8.29"},{"groupId":"OG001","value":"4.52","spread":"8.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.93","spread":"8.34"},{"groupId":"OG001","value":"4.27","spread":"8.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.31","spread":"8.81"},{"groupId":"OG001","value":"4.57","spread":"8.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)","description":"The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127.40","spread":"22.43"},{"groupId":"OG001","value":"128.42","spread":"22.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"17.01"},{"groupId":"OG001","value":"3.21","spread":"17.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.18","spread":"19.75"},{"groupId":"OG001","value":"5.10","spread":"20.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.40","spread":"19.16"},{"groupId":"OG001","value":"8.13","spread":"19.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.87","spread":"19.31"},{"groupId":"OG001","value":"7.90","spread":"19.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","spread":"19.88"},{"groupId":"OG001","value":"8.80","spread":"20.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase","description":"The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.24"},{"groupId":"OG001","value":"0.81","spread":"0.21"}]}]},{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.21"},{"groupId":"OG001","value":"0.03","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.23"},{"groupId":"OG001","value":"0.03","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.23"},{"groupId":"OG001","value":"0.06","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"-0.20","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-0.10","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase","description":"The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.34"},{"groupId":"OG001","value":"0.04","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.24"},{"groupId":"OG001","value":"0.06","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.23"},{"groupId":"OG001","value":"0.05","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase","description":"The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.24"},{"groupId":"OG001","value":"0.06","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.20"},{"groupId":"OG001","value":"0.06","spread":"0.23"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":309,"n":692},"commonTop":["INFUSION RELATED REACTION","NAUSEA","NEUTROPENIA","FATIGUE","CONSTIPATION"]}}}